Applicant identity and documented device
TransMedics, Inc. appears in FDA records at 200 Minuteman Rd., Suite 302, Andover, MA 01810, the address given on its PMA filings; this is a filing address, not a confirmed headquarters [1][3]. The legal applicant is the entity named on PMA P160013, and the cited documents do not establish parent-company structure, ownership or brand relationships beyond that name [5]. The device is the Organ Care System (OCS™) Lung System, generic name "Normothermic machine perfusion system for the preservation of standard criteria donor lungs prior to transplantation," product code QBA, device class 3 [1][2].
FDA's summary describes three major components: a reusable, non-sterile Lung Console housing the display and mechanical and electrical elements that warm, pump, ventilate and manage gas content of the perfusate; a sterile, single-use Lung Perfusion Set with an organ chamber and circulatory system; and OCS™ Lung Solution, a high oncotic solution used for ex vivo flush and perfusion when combined with packed red blood cells [4]. The system supports several ventilator modes and incorporates sensors for perfusion flow rate, airway pressure, vascular resistance, temperature, arterial and venous oxygen saturation and hematocrit [4].
Submission record in the supplied sample
The original PMA P160013 was received April 28, 2016, and approved March 22, 2018, with expedited review granted and clinical trial NCT01630434 listed [2][5]. The approval order statement covers preservation of standard criteria donor lungs in a near physiologic, ventilated and perfused state for double lung transplantation [2]. A later supplement, P160013/S002, approved May 31, 2019, expanded the indication to donor lung pairs initially deemed unacceptable for procurement based on limitations of cold static preservation [6].
Recent entries are manufacturing-related. S021, a Real-Time Process supplement received December 9, 2025 and decided May 13, 2026, covers material, supplier and design changes to the filter cap and raw material and supplier changes to the pleated filter assembly [9]. S023, a 30-Day Notice received September 28, 2026 and decided October 28, 2026, covers "a change in supplier and mold transfer of the bellows, a component of the OCS Lung System" [1][3]. An openFDA query returned 39 results for this applicant in the searched window, but the supplied excerpts show only a subset [10].
Research boundaries
The supplied material is a partial sample of FDA device records, not a complete portfolio, and it does not establish current commercial availability, sales, customers or certifications [10]. No recalls appear in the supplied data. Supplement approvals describe component, supplier or process changes and should not be read as new device approvals or as evidence of clinical performance [1][9]. Manufacturer statements on the company website, such as claims about FDA-approved use and center counts, are company assertions and are not confirmed by the FDA records supplied here [7].
